White Papers

Molecular Imaging White Papers

P. McConville & N. Ayers
October 2013

Pre-clinical imaging is playing an increasingly important role in the evaluation of new drug candidates’ therapeutic potential. With pre-clinical imaging, researchers can:

  • Evaluate drug candidates using more clinically relevant and predictive disease models 
  • Track disease progression 
  • Increase decision-making confidence 
  • Quantify endpoints that are directly translatable to clinical
    practice

Drug discovery and development scientists can employ a wide array of imaging technologies, including MRI, micro- CT, micro-PET, SPECT, X-Ray and optical (two-dimensional and fluorescence molecular tomography) to quantitatively assess test agent performance at anatomical, functional and molecular levels. Molecular imaging technologies can also be utilized to conduct applications research to develop and optimize the use of imaging, to further advance imaging in the field of drug discovery. 

V. Kaimal & P. McConville

Imaging has the potential to dramatically increase the efficiency of lead candidate selection by providing earlier and more highly predictive data, compared with traditional methods. Imaging is also well suited to facilitating translation between preclinical testing and clinical evaluation of drugs.
 

J. Chunta & P. McConville
August 2012 

Positron emission tomography (PET) imaging of metabolism with the glucose analog 2-deoxy-2-(18F)fluoro-D-glucose (FDG) has become pivotal in medical research, including oncology and inflammation disease areas, since it uniquely enables a direct measure of glucose utilization. FDG PET has transformed clinical oncology and patient management, and has also become an integral part of drug development.